Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Icotinib + Chemotherapy vs Icotinib in EGFR+ NSCLC
NCT02103257Phase 4Unknown
- Sponsor
- Betta Pharmaceuticals
- Start
- Mar 2014
- Primary completion
- Mar 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of icotinib in lung adenocarcinoma (2 arms), sponsored by Betta Pharmaceuticals. Primary endpoint: Progression Free Survival at 15 months. Status: unknown.
02
Drugs
icotinib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT02103257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02103257.